​

Arcus Biosciences (RCUS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RCUS Stock Forecast

Arcus Biosciences (RCUS) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $28.00, with a high of $35.00 and a low of $20.00. This represents a 14.66% increase from the last price of $24.42.

$10 $15 $20 $25 $30 $35 High: $35 Avg: $28 Low: $20 Last Closed Price: $24.42

RCUS Stock Rating

Arcus Biosciences stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (83.33%), 3 Hold (16.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 3 15 Strong Sell Sell Hold Buy Strong Buy

RCUS Price Target Upside V Benchmarks

TypeNameUpside
StockArcus Biosciences14.66%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-510
Avg Price Target-$26.60$27.70
Last Closing Price$24.42$24.42$24.42
Upside/Downside-8.93%13.43%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26-93--12
Feb, 26-102--12
Jan, 26192--12
Dec, 25182--11
Nov, 25372--12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 12, 2026Wells Fargo$23.00$21.367.68%-5.81%
Jan 12, 2026Richard LawGoldman Sachs$28.00$21.3031.46%14.66%
Jan 08, 2026Morgan Stanley$20.00$23.20-13.79%-18.10%
Dec 12, 2025Truist Financial$30.00$22.2734.71%22.85%
Dec 12, 2025H.C. Wainwright$32.00$22.1544.47%31.04%
Oct 30, 2025Salveen RichterGoldman Sachs$16.00$20.64-22.48%-34.48%
Oct 29, 2025Wedbush$35.00$20.2972.50%43.33%
Oct 29, 2025H.C. Wainwright$28.00$19.8840.85%14.66%
Oct 07, 2025Asthika GoonewardeneTruist Financial$39.00$14.48169.34%59.71%
May 07, 2025Eva Fortea VerdejoWells Fargo$26.00$8.12220.20%6.47%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 12, 2026Goldman SachsNeutralBuyupgrade
Dec 15, 2025UBSBuyBuyhold
Dec 12, 2025CitigroupBuyBuyhold
Dec 12, 2025H.C. WainwrightBuyBuyhold
Oct 30, 2025Goldman SachsNeutralNeutralhold
Oct 29, 2025WedbushOutperformOutperformhold
Oct 29, 2025H.C. WainwrightBuyBuyhold
Oct 13, 2025CitigroupBuyBuyhold
May 07, 2025Wells FargoOverweightOverweighthold
Oct 24, 2024CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

$-9 $-7 $-5 $-3 $-1 $1 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.76$-3.71$-4.15$-3.14$-3.29---
Avg Forecast$-4.35$-3.88$-4.00$-3.41$-4.33$-4.39$-4.67$-1.29
High Forecast$-2.48$-1.30$-3.89$-2.61$-3.13$-1.95$-2.65$0.11
Low Forecast$-7.76$-8.27$-4.18$-4.16$-5.95$-6.57$-7.29$-3.73
Surprise %-117.47%-4.38%3.75%-7.92%-24.02%---

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$383.00M$112.00M$117.00M$258.00M$247.00M---
Avg Forecast$40.33M$102.64M$113.67M$246.83M$224.94M$244.84M$260.13M$635.46M
High Forecast$64.67M$191.93M$119.63M$256.90M$484.46M$247.16M$270.13M$1.57B
Low Forecast$27.01M$50.13M$109.48M$233.02M$46.21M$242.52M$250.13M$105.36M
Surprise %849.72%9.12%2.93%4.53%9.80%---

Net Income Forecast

$-1B $-400M $200M $800M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$53.00M$-267.00M$-307.00M$-283.00M$-353.00M---
Avg Forecast$1.59B$1.43B$-307.00M$-270.00M$-385.92M$-416.98M$-429.11M$-95.16M
High Forecast$1.98B$1.80B$-221.65M$-193.25M$-231.63M$-144.22M$-195.92M$8.04M
Low Forecast$1.20B$1.05B$-392.35M$-307.63M$-440.36M$-485.96M$-539.65M$-276.34M
Surprise %-96.66%-118.73%-4.81%-8.53%---

RCUS Forecast FAQ

Is Arcus Biosciences stock a buy?

Arcus Biosciences stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Arcus Biosciences is a favorable investment for most analysts.

What is Arcus Biosciences's price target?

Arcus Biosciences's price target, set by 18 Wall Street analysts, averages $28 over the next 12 months. The price target range spans from $20 at the low end to $35 at the high end, suggesting a potential 14.66% change from the previous closing price of $24.42.

How does Arcus Biosciences stock forecast compare to its benchmarks?

Arcus Biosciences's stock forecast shows a 14.66% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Arcus Biosciences over the past three months?

  • March 2026: 0% Strong Buy, 75.00% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 83.33% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 8.33% Strong Buy, 75.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Arcus Biosciences’s EPS forecast?

Arcus Biosciences's average annual EPS forecast for its fiscal year ending in December 2026 is $-4.39, marking a 33.43% increase from the reported $-3.29 in 2025. Estimates for the following years are $-4.67 in 2027, and $-1.29 in 2028.

What is Arcus Biosciences’s revenue forecast?

Arcus Biosciences's average annual revenue forecast for its fiscal year ending in December 2026 is $244.84M, reflecting a -0.87% decrease from the reported $247M in 2025. The forecast for 2027 is $260.13M, and $635.46M for 2028.

What is Arcus Biosciences’s net income forecast?

Arcus Biosciences's net income forecast for the fiscal year ending in December 2026 stands at $-417M, representing an 18.12% increase from the reported $-353M in 2025. Projections indicate $-429M in 2027, and $-95.164M in 2028.